logo
  • 首页
  • 学术期刊
  • 论文检测
  • AIGC检测
  • 热点
  • 更多
    • 数据

Durvalumab/TremelimumabGrade 3 maculopapular rash and lack of efficacy: case report

被引:0
|
作者:
机构:
来源:
Reactions Weekly | 2024年 / 2031卷 / 1期
关键词:
D O I:
10.1007/s40278-024-69431-x
中图分类号:
学科分类号:
摘要:
引用
收藏
页码:151 / 151
相关论文
共 50 条
  • [1] TepotinibOedema, maculopapular rash and lack of efficacy: case report
    Reactions Weekly, 2025, 2043 (1) : 368 - 368
  • [2] AntibioticsGeneralised maculopapular rash and lack of efficacy: case report
    Reactions Weekly, 2025, 2049 (1) : 36 - 36
  • [3] AntineoplasticsLack of efficacy and maculopapular rash: case report
    Reactions Weekly, 2021, 1855 (1) : 45 - 45
  • [4] Regorafenib/temozolomideLack of efficacy and maculopapular rash: case report
    Reactions Weekly, 2022, 1887 (1) : 599 - 599
  • [5] AlectinibGrade 3 maculopapular rash: case report
    Reactions Weekly, 2021, 1841 (1) : 14 - 14
  • [6] Multiple drugsPruritic, maculopapular rash and lack of efficacy: 2 case reports
    Reactions Weekly, 2022, 1921 (1) : 207 - 207
  • [7] Durvalumab/infliximabPneumonitis and lack of efficacy: case report
    Reactions Weekly, 2024, 2029 (1) : 245 - 245
  • [8] AmoxicillinGeneralised maculopapular rash: case report
    Reactions Weekly, 2022, 1913 (1) : 40 - 40
  • [9] CotrimoxazoleDiffuse maculopapular rash: case report
    Reactions Weekly, 2020, 1790 (1) : 86 - 86
  • [10] IdelalisibDiffuse maculopapular rash: case report
    Reactions Weekly, 2017, 1655 (1) : 131 - 131
← 12345 →